Arca
Skip to content
Tools
Tools

Chronic obstructive pulmonary disease (COPD)

Drug research and approvals for chronic obstructive pulmonary disease (COPD): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 437 studies of chronic obstructive pulmonary disease (COPD) are recruiting on ClinicalTrials.gov, Health Canada has authorized 89 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 19 authorised medicines for it.

  • Recruiting worldwide: 437
  • Trials authorized in Canada: 89
  • FDA orphan approvals: 0
  • EU medicines: 19

Recruiting now

Newest posted first, of 437 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 20

Phase 3 12 of 50

Phase 2 12 of 96

Phase 1 or earlier 12 of 45

How its trials ended

3,551 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 913 whose ending is known, 59% met their primary endpoint, 10% missed it and 32% stopped early.

  • Completed, result not reported1,68047%
  • Met its primary endpoint53715%
  • Status unknown49014%
  • Ongoing46813%
  • Stopped: other or unclear1715%
  • Missed its primary endpoint872%
  • Stopped: enrollment or feasibility682%
  • Stopped: sponsor or business decision261%
  • Stopped: lack of efficacy13<1%
  • Stopped: funding10<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 89; search them all in Canada trials
Sep 25, 2026Alarmony: a phase 2 randomized, double blind, placebo controlled multicenter study to assess the efficacy and safety of co-administration of GSK3862995B with…GSK3862995B / GSK5784283GSKPending
Sep 14, 2026Airway dysfunction, occlusions and remodeling: COPD patients and mepolizumabHyperpolarized XENON-129Robarts Research Institute, Western UniversityPending
Sep 3, 2026A randomized, double-blind, placebo-controlled study comparing the efficacy of dupilumab added on to standard of care (SOC) treatment vs soc treatment…DupixentRegeneronPending
Jul 29, 2026An extension study to evaluate the long-term safety and efficacy of lunsekimig including inhaled corticosteroid withdrawal, in adults with chronic obstructive…Lunsekimig (SAR443765)Sanofi-Aventis Canada IncOngoing
Jun 30, 2026A randomized, double-blind, placebo-controlled, parallel arm, 52-week study to assess efficacy, safety, tolerability, and pharmacokinetics of two doses of…EXPD-101Expedition Therapeutics Inc.Ongoing
Jun 16, 2026A phase 2, multicenter, randomized, double-blind, 52-week study to investigate the efficacy and safety of brenipatide compared with placebo for the treatment…Brenipatide (LY3537031)Eli LillyPending
Dec 24, 2025An interventional phase 2/3 randomized, double-blind, third party-unblinded, placebo-controlled parallel-group study to investigate efficacy and safety of…PF-07275315PfizerOngoing
Dec 11, 2025A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on…Depemokimab (GSK3511294)GSKOngoing
Oct 22, 2025Mechanistic 129xe MRI study of single inhaler ff/umec/vi effects in COPD patients with persistent, moderate-severe dyspnea and/or poor health status with high…Hyperpolarized xenon (129XE)Robarts Research Institute, Western UniversityOngoing
Sep 3, 2025Understanding the role of airway mucus occlusions in Canadians with asthma, COPD and chronic cough (CANMUC)Hyperpolarized XENON-129McMaster UniversityPending

FDA orphan designations

Approved first, then open designations, newest first
Nov 2, 2004Sitaxsentan SodiumFor the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.Pfizer Global Research and DevelopmentDesignated
Aug 28, 2001Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasisAiroMedica LLCDesignated

Medicines authorised in the EU

Newest first; 15 of 19
Dec 18, 2018Bevespi AerosphereGlycopyrronium; formoterol fumarate dihydrateAstraZeneca ABEMA ↗
Apr 26, 2018TrydonisBeclometasone; formoterol; glycopyrronium bromideChiesi Farmaceutici S.p.A.EMA ↗
Nov 15, 2017Elebrato ElliptaFluticasone furoate; umeclidinium; vilanterolGlaxoSmithKline Trading Services LimitedEMA ↗
Nov 15, 2017Trelegy ElliptaFluticasone furoate; umeclidinium; vilanterolGlaxoSmithKline Trading Services LimitedEMA ↗
Mar 20, 2017Rolufta Ellipta (previously Rolufta)UmeclidiniumGlaxoSmithKline Trading Services LimitedEMA ↗
Nov 19, 2014Brimica GenuairAclidinium; formoterol fumarate dihydrateAzurity Pharmaceuticals Ireland Ltd.EMA ↗
Nov 19, 2014Duaklir GenuairAclidinium bromide; formoterolAzurity Pharmaceuticals Ireland Ltd.EMA ↗
May 8, 2014Laventair Ellipta (previously Laventair)Umeclidinium bromide; vilanterolGlaxoSmithKline Trading Services LimitedEMA ↗
May 8, 2014Anoro Ellipta (previously Anoro)Umeclidinium bromide; vilanterolGlaxoSmithKline Trading Services LimitedEMA ↗
Apr 28, 2014Incruse Ellipta (previously Incruse)Umeclidinium bromideGlaxoSmithKline Trading Services LimitedEMA ↗
Apr 23, 2014Ulunar BreezhalerIndacaterol; glycopyrronium bromideNovartis Europharm LimitedEMA ↗
Sep 19, 2013Ultibro BreezhalerIndacaterol; glycopyrronium bromideNovartis Europharm LimitedEMA ↗
Sep 18, 2013Xoterna BreezhalerIndacaterol; glycopyrronium bromideNovartis Europharm LimitedEMA ↗
Sep 28, 2012Tovanor BreezhalerGlycopyrronium bromideNovartis Europharm LimitedEMA ↗
Sep 28, 2012Seebri BreezhalerGlycopyrronium bromideNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.